nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—SI—Acarbose—type 2 diabetes mellitus	0.666	0.879	CbGbCtD
Scopolamine—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0254	0.0335	CbGbCtD
Scopolamine—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0226	0.0299	CbGbCtD
Scopolamine—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0164	0.0216	CbGbCtD
Scopolamine—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0112	0.0148	CbGbCtD
Scopolamine—ABCB1—Glyburide—type 2 diabetes mellitus	0.00837	0.0111	CbGbCtD
Scopolamine—ABCB1—Losartan—type 2 diabetes mellitus	0.00766	0.0101	CbGbCtD
Scopolamine—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.000279	0.00185	CcSEcCtD
Scopolamine—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000279	0.00185	CcSEcCtD
Scopolamine—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.000278	0.00185	CcSEcCtD
Scopolamine—Pharyngitis—Irbesartan—type 2 diabetes mellitus	0.000277	0.00184	CcSEcCtD
Scopolamine—Rash—Repaglinide—type 2 diabetes mellitus	0.000277	0.00184	CcSEcCtD
Scopolamine—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000276	0.00183	CcSEcCtD
Scopolamine—Eye disorder—Metformin—type 2 diabetes mellitus	0.000276	0.00183	CcSEcCtD
Scopolamine—Urinary tract disorder—Irbesartan—type 2 diabetes mellitus	0.000275	0.00183	CcSEcCtD
Scopolamine—Headache—Repaglinide—type 2 diabetes mellitus	0.000275	0.00182	CcSEcCtD
Scopolamine—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000274	0.00182	CcSEcCtD
Scopolamine—Flushing—Metformin—type 2 diabetes mellitus	0.000274	0.00182	CcSEcCtD
Scopolamine—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000274	0.00182	CcSEcCtD
Scopolamine—Urethral disorder—Irbesartan—type 2 diabetes mellitus	0.000273	0.00181	CcSEcCtD
Scopolamine—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000272	0.0018	CcSEcCtD
Scopolamine—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.00027	0.00179	CcSEcCtD
Scopolamine—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000269	0.00178	CcSEcCtD
Scopolamine—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000268	0.00178	CcSEcCtD
Scopolamine—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.000267	0.00177	CcSEcCtD
Scopolamine—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000266	0.00177	CcSEcCtD
Scopolamine—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000263	0.00175	CcSEcCtD
Scopolamine—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000263	0.00175	CcSEcCtD
Scopolamine—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000261	0.00174	CcSEcCtD
Scopolamine—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000261	0.00174	CcSEcCtD
Scopolamine—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000261	0.00173	CcSEcCtD
Scopolamine—Hypotension—Glyburide—type 2 diabetes mellitus	0.000261	0.00173	CcSEcCtD
Scopolamine—Nausea—Repaglinide—type 2 diabetes mellitus	0.000261	0.00173	CcSEcCtD
Scopolamine—Asthenia—Glipizide—type 2 diabetes mellitus	0.00026	0.00173	CcSEcCtD
Scopolamine—Pharyngitis—Losartan—type 2 diabetes mellitus	0.00026	0.00173	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.00026	0.00173	CcSEcCtD
Scopolamine—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00026	0.00172	CcSEcCtD
Scopolamine—Flushing—Irbesartan—type 2 diabetes mellitus	0.000259	0.00172	CcSEcCtD
Scopolamine—Erythema—Metformin—type 2 diabetes mellitus	0.000257	0.00171	CcSEcCtD
Scopolamine—Pruritus—Glipizide—type 2 diabetes mellitus	0.000257	0.00171	CcSEcCtD
Scopolamine—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000256	0.0017	CcSEcCtD
Scopolamine—Vertigo—Valsartan—type 2 diabetes mellitus	0.000254	0.00168	CcSEcCtD
Scopolamine—Confusional state—Gliclazide—type 2 diabetes mellitus	0.000253	0.00168	CcSEcCtD
Scopolamine—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000252	0.00167	CcSEcCtD
Scopolamine—Vertigo—Orlistat—type 2 diabetes mellitus	0.000251	0.00166	CcSEcCtD
Scopolamine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00025	0.00166	CcSEcCtD
Scopolamine—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000249	0.00165	CcSEcCtD
Scopolamine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000246	0.00164	CcSEcCtD
Scopolamine—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000246	0.00163	CcSEcCtD
Scopolamine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000245	0.00163	CcSEcCtD
Scopolamine—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000244	0.00162	CcSEcCtD
Scopolamine—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.000244	0.00162	CcSEcCtD
Scopolamine—Flushing—Losartan—type 2 diabetes mellitus	0.000244	0.00162	CcSEcCtD
Scopolamine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000243	0.00161	CcSEcCtD
Scopolamine—Erythema—Irbesartan—type 2 diabetes mellitus	0.000243	0.00161	CcSEcCtD
Scopolamine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000243	0.00161	CcSEcCtD
Scopolamine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000242	0.00161	CcSEcCtD
Scopolamine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000242	0.00161	CcSEcCtD
Scopolamine—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000242	0.0016	CcSEcCtD
Scopolamine—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000242	0.0016	CcSEcCtD
Scopolamine—Tremor—Metformin—type 2 diabetes mellitus	0.000241	0.0016	CcSEcCtD
Scopolamine—Sweating—Ramipril—type 2 diabetes mellitus	0.00024	0.0016	CcSEcCtD
Scopolamine—Dizziness—Glipizide—type 2 diabetes mellitus	0.00024	0.00159	CcSEcCtD
Scopolamine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.00024	0.00159	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000239	0.00159	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000236	0.00157	CcSEcCtD
Scopolamine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000235	0.00156	CcSEcCtD
Scopolamine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000234	0.00156	CcSEcCtD
Scopolamine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000234	0.00156	CcSEcCtD
Scopolamine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000232	0.00154	CcSEcCtD
Scopolamine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000231	0.00153	CcSEcCtD
Scopolamine—Oedema—Valsartan—type 2 diabetes mellitus	0.00023	0.00153	CcSEcCtD
Scopolamine—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00023	0.00153	CcSEcCtD
Scopolamine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00023	0.00153	CcSEcCtD
Scopolamine—Rash—Glipizide—type 2 diabetes mellitus	0.000229	0.00152	CcSEcCtD
Scopolamine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000229	0.00152	CcSEcCtD
Scopolamine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000229	0.00152	CcSEcCtD
Scopolamine—Erythema—Losartan—type 2 diabetes mellitus	0.000228	0.00152	CcSEcCtD
Scopolamine—Oedema—Orlistat—type 2 diabetes mellitus	0.000228	0.00151	CcSEcCtD
Scopolamine—Headache—Glipizide—type 2 diabetes mellitus	0.000227	0.00151	CcSEcCtD
Scopolamine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000227	0.00151	CcSEcCtD
Scopolamine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000226	0.0015	CcSEcCtD
Scopolamine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000224	0.00149	CcSEcCtD
Scopolamine—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000224	0.00149	CcSEcCtD
Scopolamine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000223	0.00148	CcSEcCtD
Scopolamine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000223	0.00148	CcSEcCtD
Scopolamine—Agitation—Irbesartan—type 2 diabetes mellitus	0.000223	0.00148	CcSEcCtD
Scopolamine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000223	0.00148	CcSEcCtD
Scopolamine—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000221	0.00147	CcSEcCtD
Scopolamine—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000221	0.00147	CcSEcCtD
Scopolamine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.00022	0.00146	CcSEcCtD
Scopolamine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000219	0.00146	CcSEcCtD
Scopolamine—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000218	0.00145	CcSEcCtD
Scopolamine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000218	0.00145	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000217	0.00144	CcSEcCtD
Scopolamine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000217	0.00144	CcSEcCtD
Scopolamine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000216	0.00144	CcSEcCtD
Scopolamine—Nausea—Glipizide—type 2 diabetes mellitus	0.000216	0.00143	CcSEcCtD
Scopolamine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Scopolamine—Hypotension—Valsartan—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Scopolamine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Scopolamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000215	0.00143	CcSEcCtD
Scopolamine—Pain—Gliclazide—type 2 diabetes mellitus	0.000215	0.00142	CcSEcCtD
Scopolamine—Constipation—Gliclazide—type 2 diabetes mellitus	0.000215	0.00142	CcSEcCtD
Scopolamine—Tremor—Losartan—type 2 diabetes mellitus	0.000214	0.00142	CcSEcCtD
Scopolamine—Rash—Glimepiride—type 2 diabetes mellitus	0.000214	0.00142	CcSEcCtD
Scopolamine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000213	0.00142	CcSEcCtD
Scopolamine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000213	0.00141	CcSEcCtD
Scopolamine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000213	0.00141	CcSEcCtD
Scopolamine—Headache—Glimepiride—type 2 diabetes mellitus	0.000212	0.00141	CcSEcCtD
Scopolamine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000212	0.0014	CcSEcCtD
Scopolamine—Agitation—Losartan—type 2 diabetes mellitus	0.00021	0.00139	CcSEcCtD
Scopolamine—Oedema—Metformin—type 2 diabetes mellitus	0.00021	0.00139	CcSEcCtD
Scopolamine—Flushing—Ramipril—type 2 diabetes mellitus	0.000209	0.00139	CcSEcCtD
Scopolamine—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000207	0.00137	CcSEcCtD
Scopolamine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000206	0.00137	CcSEcCtD
Scopolamine—Vertigo—Losartan—type 2 diabetes mellitus	0.000205	0.00136	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000205	0.00136	CcSEcCtD
Scopolamine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000205	0.00136	CcSEcCtD
Scopolamine—Skin disorder—Metformin—type 2 diabetes mellitus	0.000204	0.00135	CcSEcCtD
Scopolamine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000203	0.00135	CcSEcCtD
Scopolamine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000202	0.00134	CcSEcCtD
Scopolamine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000202	0.00134	CcSEcCtD
Scopolamine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000201	0.00134	CcSEcCtD
Scopolamine—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000201	0.00133	CcSEcCtD
Scopolamine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000201	0.00133	CcSEcCtD
Scopolamine—Asthenia—Glyburide—type 2 diabetes mellitus	0.0002	0.00133	CcSEcCtD
Scopolamine—Fatigue—Valsartan—type 2 diabetes mellitus	0.000199	0.00132	CcSEcCtD
Scopolamine—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000198	0.00132	CcSEcCtD
Scopolamine—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000198	0.00132	CcSEcCtD
Scopolamine—Oedema—Irbesartan—type 2 diabetes mellitus	0.000198	0.00132	CcSEcCtD
Scopolamine—Pruritus—Glyburide—type 2 diabetes mellitus	0.000198	0.00131	CcSEcCtD
Scopolamine—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000197	0.00131	CcSEcCtD
Scopolamine—Constipation—Valsartan—type 2 diabetes mellitus	0.000197	0.00131	CcSEcCtD
Scopolamine—Fatigue—Orlistat—type 2 diabetes mellitus	0.000196	0.0013	CcSEcCtD
Scopolamine—Hypotension—Metformin—type 2 diabetes mellitus	0.000196	0.0013	CcSEcCtD
Scopolamine—Erythema—Ramipril—type 2 diabetes mellitus	0.000196	0.0013	CcSEcCtD
Scopolamine—Pain—Orlistat—type 2 diabetes mellitus	0.000195	0.00129	CcSEcCtD
Scopolamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000194	0.00129	CcSEcCtD
Scopolamine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000194	0.00129	CcSEcCtD
Scopolamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000193	0.00128	CcSEcCtD
Scopolamine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000193	0.00128	CcSEcCtD
Scopolamine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000193	0.00128	CcSEcCtD
Scopolamine—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000192	0.00128	CcSEcCtD
Scopolamine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000191	0.00127	CcSEcCtD
Scopolamine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000191	0.00127	CcSEcCtD
Scopolamine—Dry mouth—Losartan—type 2 diabetes mellitus	0.00019	0.00126	CcSEcCtD
Scopolamine—Confusional state—Losartan—type 2 diabetes mellitus	0.000188	0.00125	CcSEcCtD
Scopolamine—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000188	0.00125	CcSEcCtD
Scopolamine—Somnolence—Metformin—type 2 diabetes mellitus	0.000187	0.00124	CcSEcCtD
Scopolamine—Oedema—Losartan—type 2 diabetes mellitus	0.000186	0.00124	CcSEcCtD
Scopolamine—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000185	0.00123	CcSEcCtD
Scopolamine—Tremor—Ramipril—type 2 diabetes mellitus	0.000183	0.00122	CcSEcCtD
Scopolamine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000183	0.00121	CcSEcCtD
Scopolamine—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000182	0.00121	CcSEcCtD
Scopolamine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000182	0.00121	CcSEcCtD
Scopolamine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000182	0.00121	CcSEcCtD
Scopolamine—Fatigue—Metformin—type 2 diabetes mellitus	0.000181	0.0012	CcSEcCtD
Scopolamine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.00018	0.0012	CcSEcCtD
Scopolamine—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.00018	0.0012	CcSEcCtD
Scopolamine—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.00018	0.0012	CcSEcCtD
Scopolamine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00018	0.00119	CcSEcCtD
Scopolamine—Agitation—Ramipril—type 2 diabetes mellitus	0.00018	0.00119	CcSEcCtD
Scopolamine—Constipation—Metformin—type 2 diabetes mellitus	0.000179	0.00119	CcSEcCtD
Scopolamine—Vomiting—Glyburide—type 2 diabetes mellitus	0.000178	0.00118	CcSEcCtD
Scopolamine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000177	0.00118	CcSEcCtD
Scopolamine—Rash—Glyburide—type 2 diabetes mellitus	0.000176	0.00117	CcSEcCtD
Scopolamine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000176	0.00117	CcSEcCtD
Scopolamine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000176	0.00117	CcSEcCtD
Scopolamine—Vertigo—Ramipril—type 2 diabetes mellitus	0.000176	0.00117	CcSEcCtD
Scopolamine—Headache—Glyburide—type 2 diabetes mellitus	0.000175	0.00116	CcSEcCtD
Scopolamine—Hypotension—Losartan—type 2 diabetes mellitus	0.000174	0.00116	CcSEcCtD
Scopolamine—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000173	0.00115	CcSEcCtD
Scopolamine—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000171	0.00113	CcSEcCtD
Scopolamine—Pain—Irbesartan—type 2 diabetes mellitus	0.000169	0.00112	CcSEcCtD
Scopolamine—Constipation—Irbesartan—type 2 diabetes mellitus	0.000169	0.00112	CcSEcCtD
Scopolamine—Nausea—Glyburide—type 2 diabetes mellitus	0.000166	0.0011	CcSEcCtD
Scopolamine—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000166	0.0011	CcSEcCtD
Scopolamine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000166	0.0011	CcSEcCtD
Scopolamine—Somnolence—Losartan—type 2 diabetes mellitus	0.000166	0.0011	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000166	0.0011	CcSEcCtD
Scopolamine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000165	0.0011	CcSEcCtD
Scopolamine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000163	0.00108	CcSEcCtD
Scopolamine—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000163	0.00108	CcSEcCtD
Scopolamine—Pruritus—Valsartan—type 2 diabetes mellitus	0.000163	0.00108	CcSEcCtD
Scopolamine—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000163	0.00108	CcSEcCtD
Scopolamine—Confusional state—Ramipril—type 2 diabetes mellitus	0.000161	0.00107	CcSEcCtD
Scopolamine—Pruritus—Orlistat—type 2 diabetes mellitus	0.000161	0.00107	CcSEcCtD
Scopolamine—Fatigue—Losartan—type 2 diabetes mellitus	0.000161	0.00107	CcSEcCtD
Scopolamine—Oedema—Ramipril—type 2 diabetes mellitus	0.00016	0.00106	CcSEcCtD
Scopolamine—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00016	0.00106	CcSEcCtD
Scopolamine—Pain—Losartan—type 2 diabetes mellitus	0.000159	0.00106	CcSEcCtD
Scopolamine—Constipation—Losartan—type 2 diabetes mellitus	0.000159	0.00106	CcSEcCtD
Scopolamine—Rash—Gliclazide—type 2 diabetes mellitus	0.000158	0.00105	CcSEcCtD
Scopolamine—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000158	0.00105	CcSEcCtD
Scopolamine—Headache—Gliclazide—type 2 diabetes mellitus	0.000157	0.00104	CcSEcCtD
Scopolamine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000157	0.00104	CcSEcCtD
Scopolamine—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000157	0.00104	CcSEcCtD
Scopolamine—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000157	0.00104	CcSEcCtD
Scopolamine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000156	0.00104	CcSEcCtD
Scopolamine—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000155	0.00103	CcSEcCtD
Scopolamine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000155	0.00103	CcSEcCtD
Scopolamine—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000154	0.00102	CcSEcCtD
Scopolamine—Dizziness—Valsartan—type 2 diabetes mellitus	0.000152	0.00101	CcSEcCtD
Scopolamine—Atropine—CYP1A2—type 2 diabetes mellitus	0.000151	0.604	CrCbGaD
Scopolamine—Dizziness—Orlistat—type 2 diabetes mellitus	0.000151	0.001	CcSEcCtD
Scopolamine—Asthenia—Metformin—type 2 diabetes mellitus	0.000151	0.001	CcSEcCtD
Scopolamine—Hypotension—Ramipril—type 2 diabetes mellitus	0.000149	0.000992	CcSEcCtD
Scopolamine—Nausea—Gliclazide—type 2 diabetes mellitus	0.000149	0.000989	CcSEcCtD
Scopolamine—Pruritus—Metformin—type 2 diabetes mellitus	0.000148	0.000986	CcSEcCtD
Scopolamine—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000147	0.000978	CcSEcCtD
Scopolamine—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000147	0.000978	CcSEcCtD
Scopolamine—Vomiting—Valsartan—type 2 diabetes mellitus	0.000147	0.000973	CcSEcCtD
Scopolamine—Rash—Valsartan—type 2 diabetes mellitus	0.000145	0.000965	CcSEcCtD
Scopolamine—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000145	0.000964	CcSEcCtD
Scopolamine—Vomiting—Orlistat—type 2 diabetes mellitus	0.000145	0.000961	CcSEcCtD
Scopolamine—Headache—Valsartan—type 2 diabetes mellitus	0.000144	0.000959	CcSEcCtD
Scopolamine—Rash—Orlistat—type 2 diabetes mellitus	0.000144	0.000953	CcSEcCtD
Scopolamine—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000143	0.000952	CcSEcCtD
Scopolamine—Headache—Orlistat—type 2 diabetes mellitus	0.000143	0.000947	CcSEcCtD
Scopolamine—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000142	0.000943	CcSEcCtD
Scopolamine—Somnolence—Ramipril—type 2 diabetes mellitus	0.000142	0.000943	CcSEcCtD
Scopolamine—Pruritus—Irbesartan—type 2 diabetes mellitus	0.00014	0.00093	CcSEcCtD
Scopolamine—Dizziness—Metformin—type 2 diabetes mellitus	0.000139	0.000921	CcSEcCtD
Scopolamine—Fatigue—Ramipril—type 2 diabetes mellitus	0.000138	0.000915	CcSEcCtD
Scopolamine—Nausea—Valsartan—type 2 diabetes mellitus	0.000137	0.000909	CcSEcCtD
Scopolamine—Constipation—Ramipril—type 2 diabetes mellitus	0.000137	0.000907	CcSEcCtD
Scopolamine—Nausea—Orlistat—type 2 diabetes mellitus	0.000135	0.000898	CcSEcCtD
Scopolamine—Asthenia—Losartan—type 2 diabetes mellitus	0.000134	0.000888	CcSEcCtD
Scopolamine—Vomiting—Metformin—type 2 diabetes mellitus	0.000133	0.000886	CcSEcCtD
Scopolamine—Rash—Metformin—type 2 diabetes mellitus	0.000132	0.000879	CcSEcCtD
Scopolamine—Dermatitis—Metformin—type 2 diabetes mellitus	0.000132	0.000878	CcSEcCtD
Scopolamine—Pruritus—Losartan—type 2 diabetes mellitus	0.000132	0.000876	CcSEcCtD
Scopolamine—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000132	0.000874	CcSEcCtD
Scopolamine—Headache—Metformin—type 2 diabetes mellitus	0.000131	0.000873	CcSEcCtD
Scopolamine—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000131	0.00087	CcSEcCtD
Scopolamine—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000126	0.000839	CcSEcCtD
Scopolamine—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000126	0.000839	CcSEcCtD
Scopolamine—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000126	0.000836	CcSEcCtD
Scopolamine—Rash—Irbesartan—type 2 diabetes mellitus	0.000125	0.000829	CcSEcCtD
Scopolamine—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000125	0.000828	CcSEcCtD
Scopolamine—Nausea—Metformin—type 2 diabetes mellitus	0.000125	0.000828	CcSEcCtD
Scopolamine—Headache—Irbesartan—type 2 diabetes mellitus	0.000124	0.000824	CcSEcCtD
Scopolamine—Dizziness—Losartan—type 2 diabetes mellitus	0.000123	0.000818	CcSEcCtD
Scopolamine—Vomiting—Losartan—type 2 diabetes mellitus	0.000119	0.000787	CcSEcCtD
Scopolamine—Nausea—Irbesartan—type 2 diabetes mellitus	0.000118	0.000781	CcSEcCtD
Scopolamine—Rash—Losartan—type 2 diabetes mellitus	0.000118	0.00078	CcSEcCtD
Scopolamine—Dermatitis—Losartan—type 2 diabetes mellitus	0.000117	0.00078	CcSEcCtD
Scopolamine—Headache—Losartan—type 2 diabetes mellitus	0.000117	0.000775	CcSEcCtD
Scopolamine—Asthenia—Ramipril—type 2 diabetes mellitus	0.000115	0.000761	CcSEcCtD
Scopolamine—Pruritus—Ramipril—type 2 diabetes mellitus	0.000113	0.000751	CcSEcCtD
Scopolamine—Nausea—Losartan—type 2 diabetes mellitus	0.000111	0.000735	CcSEcCtD
Scopolamine—Dizziness—Ramipril—type 2 diabetes mellitus	0.000106	0.000702	CcSEcCtD
Scopolamine—Vomiting—Ramipril—type 2 diabetes mellitus	0.000102	0.000675	CcSEcCtD
Scopolamine—Rash—Ramipril—type 2 diabetes mellitus	0.000101	0.000669	CcSEcCtD
Scopolamine—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000101	0.000668	CcSEcCtD
Scopolamine—Headache—Ramipril—type 2 diabetes mellitus	0.0001	0.000665	CcSEcCtD
Scopolamine—Ipratropium bromide—CYP3A4—type 2 diabetes mellitus	9.91e-05	0.396	CrCbGaD
Scopolamine—Nausea—Ramipril—type 2 diabetes mellitus	9.49e-05	0.00063	CcSEcCtD
Scopolamine—CHRM5—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.68e-06	9.44e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	8.66e-06	9.43e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—LPL—type 2 diabetes mellitus	8.66e-06	9.42e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—APOE—type 2 diabetes mellitus	8.65e-06	9.41e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—LEP—type 2 diabetes mellitus	8.65e-06	9.41e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	8.64e-06	9.4e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	8.55e-06	9.3e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.55e-06	9.3e-05	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	8.53e-06	9.28e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.52e-06	9.26e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	8.51e-06	9.26e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	8.5e-06	9.25e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	8.48e-06	9.23e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ADCY5—type 2 diabetes mellitus	8.48e-06	9.22e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	8.48e-06	9.22e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—GPX1—type 2 diabetes mellitus	8.45e-06	9.19e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	8.4e-06	9.14e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	8.4e-06	9.13e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CD36—type 2 diabetes mellitus	8.23e-06	8.95e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.16e-06	8.87e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	8.13e-06	8.84e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	8.08e-06	8.79e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	8.08e-06	8.79e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	8.08e-06	8.79e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.06e-06	8.76e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.05e-06	8.76e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.03e-06	8.73e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.98e-06	8.68e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.95e-06	8.65e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	7.95e-06	8.65e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	7.93e-06	8.62e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.88e-06	8.57e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	7.87e-06	8.56e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.87e-06	8.56e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	7.86e-06	8.55e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	7.85e-06	8.54e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.85e-06	8.54e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.84e-06	8.53e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.81e-06	8.5e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.8e-06	8.49e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	7.8e-06	8.48e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.78e-06	8.46e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	7.77e-06	8.45e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.77e-06	8.45e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.74e-06	8.42e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.72e-06	8.4e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—INS—type 2 diabetes mellitus	7.72e-06	8.39e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.72e-06	8.39e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.7e-06	8.38e-05	CbGpPWpGaD
Scopolamine—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	7.7e-06	8.38e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.7e-06	8.37e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	7.69e-06	8.36e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	7.65e-06	8.32e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.62e-06	8.29e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	7.61e-06	8.28e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.59e-06	8.26e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	7.58e-06	8.25e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.58e-06	8.24e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.55e-06	8.22e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	7.51e-06	8.17e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.49e-06	8.15e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.48e-06	8.14e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.46e-06	8.12e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.46e-06	8.12e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.46e-06	8.11e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.43e-06	8.08e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	7.41e-06	8.06e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.39e-06	8.04e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—INS—type 2 diabetes mellitus	7.39e-06	8.04e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	7.39e-06	8.04e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	7.3e-06	7.95e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	7.3e-06	7.95e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	7.29e-06	7.93e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.27e-06	7.91e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	7.26e-06	7.9e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	7.26e-06	7.9e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	7.24e-06	7.88e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	7.18e-06	7.81e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	7.17e-06	7.8e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.15e-06	7.77e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.14e-06	7.77e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	7.12e-06	7.75e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.11e-06	7.74e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.11e-06	7.74e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.09e-06	7.71e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.09e-06	7.71e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.02e-06	7.64e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	7e-06	7.62e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	7e-06	7.62e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.82e-06	7.42e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.79e-06	7.39e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.79e-06	7.38e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.77e-06	7.36e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.77e-06	7.36e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.73e-06	7.32e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.69e-06	7.28e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.67e-06	7.26e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.61e-06	7.19e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	6.54e-06	7.12e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	6.52e-06	7.09e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.48e-06	7.05e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.48e-06	7.05e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	6.46e-06	7.02e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—RELA—type 2 diabetes mellitus	6.37e-06	6.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	6.32e-06	6.88e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.24e-06	6.79e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.22e-06	6.77e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.22e-06	6.76e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	6.22e-06	6.76e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.2e-06	6.75e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—INS—type 2 diabetes mellitus	6.2e-06	6.75e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	6.2e-06	6.74e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.16e-06	6.7e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.14e-06	6.68e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	6.14e-06	6.67e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.11e-06	6.65e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	6.1e-06	6.63e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.09e-06	6.63e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	6.09e-06	6.62e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	6.09e-06	6.62e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	6.07e-06	6.6e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	6.07e-06	6.6e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.04e-06	6.57e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	6.04e-06	6.57e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.03e-06	6.56e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.02e-06	6.55e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	6.01e-06	6.54e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	6.01e-06	6.54e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	6.01e-06	6.54e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	6e-06	6.53e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.94e-06	6.46e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	5.93e-06	6.45e-05	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.8e-06	6.31e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	5.76e-06	6.26e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.74e-06	6.25e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.74e-06	6.25e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.72e-06	6.23e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.71e-06	6.21e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	5.69e-06	6.19e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.67e-06	6.17e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	5.6e-06	6.09e-05	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.55e-06	6.04e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.5e-06	5.98e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	5.5e-06	5.98e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.47e-06	5.95e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	5.44e-06	5.92e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	5.44e-06	5.92e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.43e-06	5.91e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.43e-06	5.91e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.42e-06	5.89e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	5.38e-06	5.85e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.37e-06	5.84e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.36e-06	5.83e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	5.36e-06	5.83e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.26e-06	5.73e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	5.22e-06	5.68e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	5.2e-06	5.66e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.2e-06	5.66e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	5.19e-06	5.64e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	5.16e-06	5.61e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.14e-06	5.6e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	5.14e-06	5.59e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.12e-06	5.57e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.1e-06	5.55e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.05e-06	5.5e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.04e-06	5.48e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.03e-06	5.47e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.03e-06	5.47e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.02e-06	5.46e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.01e-06	5.45e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.01e-06	5.45e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	5e-06	5.44e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.99e-06	5.43e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	4.97e-06	5.41e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.97e-06	5.4e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.96e-06	5.4e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	4.95e-06	5.38e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.94e-06	5.38e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.87e-06	5.3e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	4.85e-06	5.28e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	4.79e-06	5.21e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.78e-06	5.2e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.76e-06	5.18e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.72e-06	5.13e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	4.7e-06	5.11e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.67e-06	5.08e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	4.62e-06	5.03e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	4.61e-06	5.01e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.56e-06	4.96e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.56e-06	4.96e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	4.55e-06	4.95e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.55e-06	4.95e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.55e-06	4.95e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.5e-06	4.9e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.5e-06	4.9e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.47e-06	4.87e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.39e-06	4.77e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	4.29e-06	4.67e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.28e-06	4.66e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	4.28e-06	4.66e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	4.24e-06	4.61e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.2e-06	4.57e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	4.01e-06	4.36e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—INS—type 2 diabetes mellitus	3.94e-06	4.28e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.91e-06	4.25e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.9e-06	4.24e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.87e-06	4.21e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.86e-06	4.2e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.86e-06	4.2e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.85e-06	4.19e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.84e-06	4.17e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.82e-06	4.16e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.8e-06	4.13e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.66e-06	3.98e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.65e-06	3.97e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.62e-06	3.94e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.61e-06	3.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.61e-06	3.93e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	3.61e-06	3.92e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.57e-06	3.89e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.55e-06	3.86e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.54e-06	3.85e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.5e-06	3.81e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	3.45e-06	3.75e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	3.45e-06	3.75e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.37e-06	3.67e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	3.37e-06	3.67e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	3.36e-06	3.66e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	3.33e-06	3.62e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.29e-06	3.58e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.28e-06	3.56e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.24e-06	3.53e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	3.23e-06	3.51e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	3.16e-06	3.43e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.11e-06	3.38e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.02e-06	3.28e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.01e-06	3.27e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.98e-06	3.24e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.98e-06	3.24e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.96e-06	3.22e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.95e-06	3.21e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.92e-06	3.18e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	2.5e-06	2.72e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.27e-06	2.47e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.27e-06	2.46e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.24e-06	2.44e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.1e-06	2.28e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.09e-06	2.27e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.07e-06	2.25e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	1.59e-06	1.73e-05	CbGpPWpGaD
